Vaxcyte releases September investor presentation
PCVX•September investor presentation highlights VAX-31 progress
- Vaxcyte released an investor presentation outlining its pneumococcal conjugate vaccine strategy, led by its 31-valent candidate VAX-31.
- Enrollment has been completed in three Phase 3 adult trials for VAX-31, including OPUS-1, a pivotal noninferiority study.
- Topline OPUS-1 adult data are expected by the end of October 2026, while OPUS-2 and OPUS-3 readouts are targeted for the first half of 2027.
- Cash, cash equivalents and investments totaled about $2.5 billion as of June 30, 2026.
- The presentation also highlights earlier-stage programs in Group A strep and Shigella, leveraging the company’s cell-free protein synthesis platform.
